L3HARRIS Technologies
L3HARRIS TECHNOLOGIES, INC.
Key figures
Period 2023-12-30 to 2025-01-03ConsolidatedU.S. GAAP
RevenueDisclosed
US$21.3B
Operating marginCalculated
9.0%
Net assets to total assetsCalculated
46.5%
Company profile
Tables scroll sideways
Disclosed data
Profitability
★★★☆☆position among all companies
9.0%
Growth (revenue, 4-year average)
★★★☆☆position among all companies
4.0%
Capital efficiency
★★☆☆☆position among all companies
7.7%
Revenue and profit
Performance, financial position and capital allocation
L3HARRIS Technologies
Recent performance trends
L3HARRIS Technologies
Cash flow trends
Consolidated indicators (9 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$18.2 billion | US$17.8 billion | US$17.1 billion | US$19.4 billion | US$21.3 billion |
| Operating income | US$2.2 billion | US$2.1 billion | US$1.1 billion | US$1.4 billion | US$1.9 billion |
| Net income | US$1.1 billion | US$1.8 billion | US$1.1 billion | US$1.2 billion | US$1.5 billion |
| Total assets | US$37.0 billion | US$34.7 billion | US$33.5 billion | US$41.7 billion | US$42.0 billion |
| Shareholders' equity | US$20.7 billion | US$19.2 billion | US$18.5 billion | US$18.8 billion | US$19.5 billion |
| Net cash provided by (used in) operating activities | US$2.8 billion | US$2.7 billion | US$2.2 billion | US$2.1 billion | US$2.6 billion |
| Net cash provided by (used in) investing activities | US$0.8 billion | US$1.4 billion | US$-0.2 billion | US$-7.0 billion | US$-0.3 billion |
| Net cash provided by (used in) financing activities | US$-3.1 billion | US$-4.4 billion | US$-2.0 billion | US$4.6 billion | US$-2.2 billion |
| Cash and cash equivalents | US$1.3 billion | US$0.9 billion | US$0.9 billion | US$0.6 billion | US$0.6 billion |
Revenue scale in the same industry
L3HARRIS Technologies
Instruments and medical devices: 43 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Thermo Fisher ScientificFY Dec 2025 US$44.6B
- 2 Northrop Grumman Corp /DE/FY Dec 2025 US$42.0B
- 3 MedtronicFY Apr 2026 US$36.4B
- … 3 companies
- 7 DanaherFY Dec 2025 US$24.6B
- 8 BECTON, Dickinson ANDFY Sep 2025 US$21.8B
- 9 L3HARRIS TechnologiesThis companyFY Jan 2025 US$21.3B
- 10 GE Healthcare TechnologiesFY Dec 2025 US$20.6B
- 11 Boston ScientificFY Dec 2025 US$20.1B
- … 32 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$0.4 billion | Consolidated | Disclosed |
| Cash and cash equivalents | US$0.6 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$-2.2 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-0.3 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$2.6 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$1.3 billion | Consolidated | Disclosed |
| Dividends paid | US$0.9 billion | Consolidated | Disclosed |
| Number of employees | 45,000 | Consolidated | Disclosed |
| Stockholders' equity (including non-controlling interests) | US$19.6 billion | Consolidated | Disclosed |
| Non-controlling interests | US$65.00 million | Consolidated | Disclosed |
| Net assets | US$19.5 billion | Consolidated | Disclosed |
| Net sales | US$21.3 billion | Consolidated | Disclosed |
| Operating income | US$1.9 billion | Consolidated | Disclosed |
| Net income | US$1.5 billion | Consolidated | Disclosed |
| Total assets | US$42.0 billion | Consolidated | Disclosed |
| Purchase of treasury stock | US$0.6 billion | Consolidated | Disclosed |
| Operating margin | 9.0% | Consolidated | Calculated |
| Net assets to total assets | 46.5% | Consolidated | Calculated |
| Net margin | 7.0% | Consolidated | Calculated |
| Return on equity | 7.7% | Consolidated | Calculated |